LMMY
L A M Y0.3534
+0.0034+0.97%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
24.74MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Exousia Bio posted no revenue for Q2 FY2026 ended November 30, 2025, versus none prior year, with $62,108 COGS driving gross loss while operating expenses jumped to $174,897 from $6,981 (y/y) on R&D ramp-up post-Exousia AI acquisition. Gain on acquisition of $217,922 narrowed net loss to $19,083 from prior year's $80,129 profit; operating loss exceeded net by less than 20%. Closed Exousia AI November 17, 2025 for 62,223,000 shares (stock), booking $22.05M Other Assets (Exousia AI). No cash or debt; $261K current liabilities met related-party advances. Shares outstanding ballooned to 70M. Development-stage biotech needs capital. Going concern doubts linger.
8-K
LAMY acquires Exousia Ai
LAMY closed its acquisition of Exousia Ai on November 17, 2025, issuing 62,223,000 common shares to make it a wholly-owned subsidiary. Zhang Shengwu resigned as sole officer and director; Matthew Dwyer took over. Exousia Ai brings FDA Orphan Drug Designation for GBM and plant-based exosome tech targeting oncology, cosmeceuticals. Change of control dilutes prior owners sharply.
10-Q
Q1 FY2026 results
Lamy posted zero revenue for Q1 FY2026 ended August 31, 2025, down from $3,750 y/y, driving a net operating loss of $31,814—up sharply from $4,342 y/y amid $31,814 operating expenses (professional fees $20,750, OTC fees $7,500). No q/q available. Losses match across operating and net lines. Cash stayed at zero, propped by $3,500 related-party advances matching financing inflows; total liabilities hit $35,314 from related parties, with equity deficit at $35,314. Change in control came December 2024 when Zhang Shengwu grabbed 64.29% voting shares. No revenues yet. Going concern doubts loom large.
10-K
FY2025 results
LAMY's fiscal year ended May 31, 2025, delivered $3,750 in revenue, down from $11,500 the prior year, yet swung to a $51,395 net income from a $25,807 loss, driven by slightly higher operating expenses of $31,843 versus $28,076. The December 2024 change in control to Shengwu Zhang stabilized leadership without altering the eLearning game strategy. Cash dwindled to zero by year-end, with operating cash use at $4,528, offset by $3,500 in financing inflows. No quarterly breakdowns disclosed. Liquidity remains precarious. Risks include failure to secure funding, threatening operations.
10-Q
Q3 FY2025 results
Lamy swung to a nine-month net profit of $54,895 through February 28, 2025, up from a $20,554 loss a year earlier, fueled by $86,739 in other income that offset $35,594 in general and administrative expenses, while revenue dipped to $3,750 from $7,750 y/y. The quarter ended with no revenue but a $61,883 pre-tax gain, reversing a $4,820 loss q/q, thanks to that same other income boost. Debt forgiveness wiped the balance sheet clean, leaving zero cash, assets, and liabilities. Change in control hit December 6, 2024, with Zhang Shengwu grabbing 64.29% of shares. Operating cash drained $1,028 y/y (derived). No free cash flow disclosed in the 10-Q. Yet going concern doubts linger.
AMBO
Ambow Education Holding Ltd. Am
3.65+0.04
BRWC
BIRDIE WIN CORP.
0.40+0.00
FEDU
Four Seasons Education (Cayman)
11.42+0.21
GV
Visionary Holdings Inc.
1.38-0.02
KIDZ
Classover Holdings, Inc.
0.28+0.02
MYND
Mynd.ai, Inc.
0.55-0.02
TAL
TAL Education Group
11.16-0.07
UDMY
Udemy, Inc.
5.37+0.10
VSA
VisionSys AI Inc.
0.10-0.01
YQ
17 Education & Technology Group
3.73-0.10